Company: SHPH
Filing Date: 2025-04-10
Form Type: PRER14A
Source: 0001641172-25-003635
Chunk: 3

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-04-10
Form: PRER14A
Chunk 3
---
 clinical trial, working with colleagues at MedStar-Georgetown University
Hospital, and expanding to a multi- institutional clinical trial as resources become available.

For our PSMA-B development program, we have entered into a sponsored research agreement with the University of California, San Francisco
(UCSF) to advance pre-clinical development as a potential diagnostic and therapeutic, or theranostic, molecule. In a discovery project
to develop a novel, boron- containing PSMA ligand to enhance proton radiation therapy of prostate cancer, we observed that the PSMA-B molecule containing boron and demonstrating nanomolar binding activity to PSMA also offered the potential for imaging metastatic prostate
cancer. Preclinical evaluations have been initiated
to explore the PSMA-B ligand as a potential prostate cancer sensitizer in combination with proton therapy, as well as a PET diagnostic
reagent and as a targeted prostate cancer therapeutic. The agreement with UCSF will support further preclinical testing in a mouse model
of prostate cancer for its potential to bind to prostate cancer deposits in mice.

Our intellectual property
within both diagnostic programs (PC-Rad and PSMA-B ligand) offers an opportunity for further development through a potential Shuttle
Diagnostics spin-out.

ENHANCED BUSINESS FOCUS

With scientific and clinical trial activities accelerating, Christopher Cooper has been appointed as interim Chief Executive Officer,
focused on enhancing capital markets and business capabilities. Christopher brings a wealth of business experience which, when balanced
with the inherent scientific expertise of the Shuttle Pharma team, should allow for a more effective executive structure to inspire confidence
going forward.

We have also appointed
three new members to our board of directors (George Scorsis, Oleh Nabyt and Joseph Tung), offering business and legal backgrounds to help guide the Company going forward. In connection with appointments of new members, Dr. Milton
Brown, Dr. Chris Senanayake, Dr. Bette Jacobs and Mr. Joshua Schafer resigned from their positions. I personally thank Drs. Brown, Senanayake,
Jacobs and Mr. Schafer for their contributions to the company.

As a pre-revenue discovery
and developmental company, we are dependent on expanding our access to the capital markets, and most recently, we completed a $5.75 million
straight common stock offering in March 2025 to support the Phase 2 clinical trial for Ropidoxuridine and RT, for marketing and advertising
services, and for working capital and general corporate purposes.